TheraRadar
Clinical-Stage Companies / Staidson (Beijing) Biopharmaceuticals

Staidson (Beijing) Biopharmaceuticals

Pre-Approval PRO BETA
27
Total Trials
3
Phase 3
11
Phase 2
4
Recruiting
197
Score

Pipeline by Phase

Phase 3
3
Phase 2
11
Phase 1
18

Therapeutic Focus

Healthy Hemophilia Oligozoospermia Neurotrophic Keratitis Healthy Subject

Clinical Trials (27)

NCT07168161 Phase 3 RECRUITING

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

Started: 11/10/2025

NCT07208591 Phase 3 RECRUITING

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Started: 10/31/2025

NCT06975748 Phase 2 RECRUITING

A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis

Started: 6/12/2025

NCT06289166 Phase 2 COMPLETED

Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor

Started: 3/18/2024

NCT04449588 Phase 2 TERMINATED

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

Started: 7/23/2020

NCT05619926 Phase 2 COMPLETED

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Started: 1/9/2023

NCT05760703 Phase 2 TERMINATED

Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Started: 4/25/2023

NCT05760781 Phase 2 TERMINATED

To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Started: 4/25/2023

NCT05093855 Phase 2 COMPLETED

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Started: 8/18/2021

NCT06948799 Phase 1 RECRUITING

A Study to Evaluate the Safety and Tolerability of Single and Multiple Dose of STSP-0902 in Healthy Subjects

Started: 5/8/2025

NCT06597422 Phase 1 COMPLETED

A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects

Started: 10/20/2024

NCT05197842 Phase 1 COMPLETED

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Started: 2/22/2022

NCT06038916 Phase 1 COMPLETED

To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Started: 12/9/2023

NCT06563713 Phase 1 COMPLETED

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects

Started: 7/31/2024

NCT05027230 Phase 1 COMPLETED

A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Started: 10/12/2021

NCT04747964 Phase 1 COMPLETED

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Started: 1/15/2020

NCT06148389 Phase 1 COMPLETED

The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects

Started: 11/16/2023

NCT05986877 Phase 1 COMPLETED

A Study of STSA-1201 in Healthy Subjects

Started: 8/4/2023

NCT05559125 Phase 1 TERMINATED

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

Started: 11/8/2022

NCT05075304 Phase 1 TERMINATED

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

Started: 2/21/2020

NCT05103423 Phase 1 COMPLETED

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Started: 6/24/2021

NCT05166837 Phase 1 COMPLETED

The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects

Started: 1/10/2022

NCT05702983 Phase 1 COMPLETED

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Started: 1/31/2023

NCT05497635 Phase 1 COMPLETED

A Study of STSA-1002 in Healthy Subjects

Started: 10/14/2022

NCT05360927 Phase 1 COMPLETED

Safety and Tolerability of BDB-001 Injection in Healthy Subjects

Started: 9/25/2019

NCT05361005 Phase 1 COMPLETED

Tolerability and Safety of BDB-001 Injection in Healthy Subjects

Started: 3/12/2020

NCT05032144 Phase 1 COMPLETED

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

Started: 9/28/2021

Drug Candidates

STSP-0902 injection BDB-001 injection STSP-0902 ophthalmic solution STSA-1002 injection STSA-1002 Injection STSP-0601 for Injection STSA-1301 subcutaneous injection STSA-1201 Subcutaneous injection BDB-001 Injection STSA-1005 Injection
Activity Status: Active
Last Trial Started: 11/10/2025
Last Trial Ended: 4/27/2025
Trials (12 months): 2
Completed Trials: 18
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.